Expression of hypoxia-inducible factor-1|[alpha]| predicts benefit from hypoxia modification in invasive bladder cancer

Bladder cancer is common, with over 10 000 new diagnoses in the United Kingdom in 2010 (Kreimer et al, 2005; CRUK, 2013). Conventional treatment for muscle-invasive disease involves radiotherapy (RT) or radical cystectomy, which have similar survival rates (Dunst et al, 2001). Five-year overall survival (OS) is only around 58% for men and 50% for women (Klussmann et al, 2003). There is therefore a need for improved treatment strategies. The BCON (bladder carbogen and nicotinamide) phase III clinical trial showed that addition of carbogen and nicotinamide (CON) to RT improved OS (Hoskin et al, 2010). Adding gemcitabine (Choudhury et al, 2011) or fluorouracil and mitomycin C (James et al, 2012) to RT also improves outcomes. Biomarkers are required to predict benefit from the different approaches to individualise treatment. Hypoxic tumours benefit most from hypoxia modification (Kaanders et al, 2002; Rischin et al, 2006; Janssens et al, 2012; Toustrup et al, 2012). As direct measurement of hypoxia is invasive and impractical, analysis of pathological features and surrogate hypoxia markers may be preferable. In support, we showed previously that tumour necrosis is an independent prognostic factor in invasive bladder cancer, and both necrosis and expression of the hypoxia-inducible enzyme carbonic anhydrase IX (CAIX) predicted benefit from hypoxia modification (Eustace et al, 2013a). In contrast, a 26-gene hypoxia signature did not predict benefit from RT+CON in BCON (Eustace et al, 2013b). In this study, we explored hypoxia-inducible factor (HIF). HIF-1 is a transcription factor that transactivates genes implicated in cancer development, including contributors to angiogenesis and anaerobic metabolism (Shweiki et al, 1992; Elbert et al, 1996). The subunit hypoxia-inducible factor-1α (HIF-1α), which accumulates in response to cellular hypoxia, correlates with stage, grade and metastatic potential of bladder cancers (Wang et al, 1995; Deniz et al, 2010). Moreover, HIF-1α and the downstream proteins CAIX and glucose transporter 1 (GLUT1) are all independent prognostic factors in bladder cancer (Hoskin et al, 2003; Palit et al, 2005; Theodoropoulos et al, 2005; Ord et al, 2007; Chai et al, 2008; Deniz et al, 2010). As tumour necrosis represents an attractive prognostic and predictive factor that is relatively simple to assess, it remains unclear whether the addition of hypoxia markers will improve our ability to predict benefit from CON. We hypothesised that as HIF-1α has an important role in mediating the cellular response to tumour hypoxia, it may improve patient stratification. Therefore, we performed a retrospective study to explore whether expression of combinations of necrosis, HIF-1α, CAIX and GLUT1 predict benefit from hypoxia modification. We also compared the predictive ability of quantitative CAIX or GLUT1 gene expression with immunohistochemistry. Samples were taken from patients enrolled in the BCON trial. REMARK guidelines for prognostic tumour marker studies were followed (McShane et al, 2005). Trial protocol and sample acquisition were described previously (Hoskin et al, 2010; Eustace et al, 2013a). In brief, patients were randomised to RT alone or RT plus carbogen (2% CO2+98% O2) and nicotinamide (40 or 60 mg kg−1). Pre-treatment tissue samples were obtained via transurethral resection of the bladder tumour and formalin-fixed and paraffin-embedded blocks were constructed. Figure 1 shows the study CONSORT diagram. Analysis of HIF-1α expression was possible in a subset of 137 patients enrolled in the BCON trial. HIF-1α data were not obtained for some patients because of poor stain uptake or TMA degradation. Data for CAIX and GLUT1 expression were available for 138 and 127 patients, respectively. Table 1 shows the distribution of clinicopathological parameters by HIF-1α expression. Patients with high tumour expression of HIF-1α also had high expression of CAIX (P=0.004) and GLUT1 (P=0.006), and tended to have more necrosis (P=0.07). Analyses for OS and LRFS were performed, but owing to similarity in results, data for LRFS only are presented. Univariate and multivariate prognostic analyses for patients receiving the standard treatment of RT alone showed that neither HIF-1 α (n=74), CAIX (n=73) nor GLUT1 (n=70) were prognostic in patients receiving RT alone (P>0.29). Age (P=0.04) and necrosis (P=0.01) were the only prognostic factors in the univariate analysis, but neither was significant in multivariate analysis. Multivariate analyses were performed on a smaller cohort of 133 patients, as those with missing data for any clinicopathological or immunohistochemical variable were excluded. Forward stepwise analysis including both treatment arms stratified by HIF-1α expression showed that age (1.65, 95% CI 1.06–2.57, P=0.03) and treatment in the presence of high HIF-1α (HR 0.49, 95% CI 0.27–0.90, P=0.02) were statistically significant prognostic factors (Table 2). Treatment was not a significant prognostic factor in those with low HIF-1α expression (P=0.55). Kaplan–Meier survival analyses are presented in Figures 2, 3, 4. Hazard ratios for RT+CON compared with RT alone for patients with high or low HIF-1α, CAIX and GLUT1 expression are presented in Table 3. Also shown are HRs for combinations of these markers and combinations with necrosis. Five-year LRFS was 46% in patients receiving RT+CON and 38% in those receiving RT alone. In patients with high HIF-1α expression, there was a statistically significant improvement in 5-year LRFS in those receiving RT+CON (47%) compared with RT alone (21%) (P=0.02). Similarly, in those with high CAIX expression, 5-year LRFS was improved with RT+CON (52%) vs RT alone (25%) (P=0.006). Patients with combinations of high HIF-1α and CAIX expression or high CAIX and GLUT1 expression had improved 5-year LRFS with RT+CON (61% and 47%, respectively) compared with RT alone (16% and 18%, respectively, P=0.01 and 0.03). Patients with necrosis plus high HIF-1α, CAIX or GLUT1 expression all had significant improvements in LRFS with RT+CON (57%, 54% and 66%, respectively) vs RT alone (19%, 28% and 25%, respectively, P=0.01, 0.02 and 0.01). There was no improvement in LRFS in patients with high expression of the CAIX gene receiving RT+CON compared with RT (HR 0.92, 95% CI 0.49–1.75, P=0.81). Similarly, no benefit from CON was seen in those with high GLUT1 gene expression (HR 0.66, 95% CI 0.38–1.14, P=0.14). There was no correlation between CAIX gene and protein expression (r=−0.02) and only weak correlation between GLUT1 gene and protein expression (r=0.39). Hypoxia is of critical importance in cancer treatment. It contributes to tumour progression, invasiveness, metastasis and resistance to both chemotherapy and RT (Gray et al, 1953; Deschner and Gray, 1959; Brown, 2000; Harris, 2002). In bladder cancer, there is evidence that hypoxia modification improves locoregional control after RT (Overgaard and Horsman, 1996) and the BCON trial showed significant improvements in OS, risk of death and local relapse for patients receiving RT+CON (Hoskin et al, 2010). Furthermore, significant improvements in 5-year regional control with RT+CON were observed in patients with hypoxic laryngeal cancers; those with well-oxygenated tumours received no benefit (Janssens et al, 2012). Our findings support the notion that patients without evidence of tumour hypoxia do not receive benefit from hypoxia modification. For such patients, alternative methods of radiosensitisation such as concurrent gemcitabine (Choudhury et al, 2011) or fluorouracil and mitomycin C (James et al, 2012) should be considered. There is a clear need to stratify patients according to the presence of tumour hypoxia. Future work is planned to investigate the relationship between necrosis and outcomes in patients enrolled in the BC2001 trial that randomised to RT alone or with 5-fluorouracil and mitomycin. The latter study will investigate whether patients with necrosis in their tumours benefit from the addition of fluorouracil and mitomycin C to RT. Direct measurement of hypoxia via Eppendorf electrodes is difficult in bladder cancer owing to tumour inaccessibility, and while pimonidazole binding is a widely accepted surrogate it is invasive and impractical. Our previous work showed that tumour necrosis is an attractive and easily assessable factor that may be used to predict benefit from hypoxia modification in bladder cancer (Eustace et al, 2013a). Coagulative tumour necrosis, the subtype studied here is thought to be specific to tumour hypoxia. In addition, analysis of hypoxia-associated proteins is attractive because of the simplicity of obtaining paraffin-embedded material. Before HIF-1α, CAIX or GLUT1 can be used clinically they must be validated as intrinsic markers of tumour hypoxia. In support, their expression correlates with pO2 and co-localises with pimonidazole in cervical cancer (Airley 2001, Haugland 2002, Jankovic 2006 and Dellas 2008). There is also significant co-localisation of CAIX and GLUT with pimonidazole in bladder cancer Hoskin et al, 2003. Although there are no current data correlating HIF-1α expression with pimonidazole binding in bladder cancer, our work did suggest that patients with high HIF-1α expression also tended to have higher expression of CAIX and GLUT1. Analysis of a larger cohort of the BCON patients showed tumour necrosis is a prognostic factor in bladder cancer (Eustace et al, 2013a). The loss of significance in multivariate analysis in the current analysis is due to reduced patient numbers owing to adding another variable. Although our results suggest that HIF-1α, GLUT1 and CAIX are not prognostic, this is not consistent with other studies and may be due to differences in analytical techniques, sample heterogeneity, the limitations of TMA analysis or most likely the small number of patients in the RT only arm (Hoskin et al, 2003; Theodoropoulos et al, 2005). Tumour necrosis was strongly predictive of benefit from CON and is clinically very appealing owing to its simplicity and wide availability. HIF-1α is a hypoxia-inducible marker, which we show for the first time predicts benefit from CON. Kaplan–Meier analyses showed that CAIX was also predictive in the cohort studied here, as we reported previously with a larger group (Eustace et al, 2013a). The findings that combined expression of HIF-1 or GLUT1 with CAIX retained predictive ability supports the notion that tumour hypoxia may be best assessed using multiple markers. Furthermore, analysis of necrosis in combination with HIF-1α, CAIX or GLUT1 may be a viable option, as this improved the predictive value of HIF-1α and CAIX. However, it is important to note that combinations of hypoxia-specific markers alone or with necrosis did not improve upon the prognostic or predictive ability of necrosis alone. A limitation of our study was the lack of a validation cohort to confirm our findings, but unfortunately there is no other trial that randomised patients to RT alone or with CON. Previous work established a hypoxic gene signature that may predict response to hypoxia-modifying therapy (Eustace et al, 2013b). The signature predicted response to CON in laryngeal cancers but not in bladder tumours, which may reflect highly conserved genetic alterations specific to bladder cancer (Eustace et al, 2013b). Our findings that CAIX gene expression did not correlate with protein expression may offer some explanation as to why the signature was not predictive. The finding differs from our observations in head and neck cancers, where CAIX protein and gene expression correlated (Winter et al, 2007). At present immunohistochemical analysis of protein expression seems more favourable than gene expression analysis in bladder cancer, but neither of them seem to improve upon the utility, simplicity and availability of tumour necrosis. BCON is currently a routine treatment for bladder cancer in some UK centres. Our data suggest that BCON is more effective in those with evidence of necrosis or hypoxia marker expression. Although HIF-1α could be used to predict benefit from CON, it does not improve on the simple assessment of necrosis alone. The authors declare no conflict of interest. This work was supported by, Cancer Research UK (C2094/A11365), the MRC Biomarker grant (G0801525) and Experimental Cancer Medicine Centre funding (C1467/A7286). Author contributions BAH carried out the HIF work, the analyses and wrote the paper; AE, AC, HRV, JJL and CMW supervised the project; HD carried out pathology assessments; RS oversaw or carried out statistical analyses; all authors read the paper and provided feedback. Supplementary Information accompanies this paper on British Journal of Cancer website